Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED)

Allergies Clinical Trial

Official title:

A Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00779116
• Other study ID #: P04574
• Status: Completed
• Phase: Phase 4
• Start date: September 2005
• Est. completion date: October 2005

Study information

• Verified date: February 2022
• Source: Organon and Co
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This was a randomized, open-label, 2-way cross-over study, comparing desloratadine RediTab 2.5 mg to a marketed chewable antihistamine oral medication (Zyrtec® 5 mg

Chewable Tablet). Subject preference for one product or the other was determined. Acceptability of product attributes (Taste and Feeling in the Mouth) was rated using a "smile" face scale.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 217
• Est. completion date: October 2005
• Est. primary completion date: October 2005
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Years to 11 Years

Eligibility

Inclusion Criteria:

• Subject, and the parent/guardian of the subject, was to have demonstrated their willingness to participate in the study and comply with its procedures by signing a written Informed Consent.

• Subject was to be 6-11 years of age, of either sex and of any race.

• If female, subject was to be premenarcheal.

• Subject was to be willing to avoid eating, drinking, gum chewing, and teeth brushing for one hour prior to enrollment.

• Subject was to be free of any clinically significant disease that would interfere with study evaluations, including allergic rhinitis and respiratory infections.

• Subject was to have understood and been able to adhere to the dosing and visit schedules.

Exclusion Criteria:

• If female, subject who was pregnant, intended to become pregnant during the study or nursing.

• Subject had used any investigational product within 30 days prior to enrollment.

• Subject had any of the following clinical conditions: history of any significant medical conditions (based on reporting by parent or guardian): e.g., diabetes, heart disease, liver disease, kidney disease, breathing problems, cough with excessive phlegm, or persistent or chronic cough.

• Subject had a current medical condition that, in the opinion of the Investigator or designee, may interfere with the ability to discriminate taste (e.g., common cold, sinus infection, bronchial infection, allergic rhinitis, etc.).

• Subject was participating in any other clinical study(ies).

• Subject was part of the staff or a family member of the staff personnel directly involved with this study.

• Subject was allergic to or has sensitivity to the study drug or its excipients.

• Subject had a history of allergic reaction to prescription and/or OTC medications and/or food products.

• Subject had used any antihistamines within 24 hours prior to tasting as outlined in Section 9.4.7.

• Subject used sedatives, tranquilizers, or monoamine oxidase inhibitor drugs.

Related Conditions & MeSH terms

• Allergies

Intervention

Drug:
• Desloratadine
SCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day
• Zyrtec® (cetirizine)
Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Organon and Co

References & Publications (1)

Tassinari P, Suárez NR, Centeno J, Velásquez JV, Aguirre-Mariscal H, Gonzálezdíaz SN, Jerves AF; LA Desloratadine Study Group. Desloratadine therapy improves allergic rhinitis symptoms in latin american children aged 6 to 12 years. World Allergy Organ J. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects Who Preferred Desloratadine RediTab or Zyrtec Chewable Tablet.	A product preference questionnaire was completed after the administration of the second study drug. An interviewer instructed the subject "now that you have tasted the two tablets, show us which tablet you like more" and the subject then marked which tablet he/she preferred. If the subject had no preference, the response was recorded accordingly.	Following the second dose (8-10 minutes after the first dose)